

# Jean-Simon Diallo

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4723435/jean-simon-diallo-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69

papers

2,782

citations

28

h-index

52

g-index

73

ext. papers

3,278

ext. citations

9.9

avg, IF

4.66

L-index

#	Paper	IF	Citations
69	Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. <i>Nature</i> , <b>2011</b> , 477, 99-102	50.4	392
68	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. <i>Molecular Therapy</i> , <b>2012</b> , 20, 749-58	11.7	177
67	Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	164
66	Intelligent design: combination therapy with oncolytic viruses. <i>Molecular Therapy</i> , <b>2010</b> , 18, 251-63	11.7	150
65	Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 14981-6	11.5	146
64	A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. <i>Molecular Therapy</i> , <b>2011</b> , 19, 1913-22	11.7	117
63	Expression and nuclear localization of ErbB3 in prostate cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2730-2.9	12.9	99
62	Synergistic interaction between oncolytic viruses augments tumor killing. <i>Molecular Therapy</i> , <b>2010</b> , 18, 888-95	11.7	97
61	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. <i>Nature Medicine</i> , <b>2015</b> , 21, 530-6	50.5	93
60	HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. <i>Molecular Therapy</i> , <b>2013</b> , 21, 887-94	11.7	85
59	Does Treatment Order Matter? Investigating the Ability of Bacteriophage to Augment Antibiotic Activity against Biofilms. <i>Frontiers in Microbiology</i> , <b>2018</b> , 9, 127	5.7	79
58	A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. <i>Molecular Therapy</i> , <b>2010</b> , 18, 1123-9	11.7	67
57	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. <i>Cancer Cell</i> , <b>2015</b> , 28, 210-24	24.3	62
56	Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. <i>Molecular Therapy</i> , <b>2012</b> , 20, 1791-9	11.7	56
55	Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds. <i>Molecular Therapy</i> , <b>2018</b> , 26, 56-69	11.7	55
54	Oncolytic Viruses: Exploiting Cancer's Deal with the Devil. <i>Trends in Cancer</i> , <b>2015</b> , 1, 266-277	12.5	54
53	Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. <i>PLoS ONE</i> , <b>2010</b> , 5, e14462	3.7	54

52	Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 83	8.3	53
51	From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. <i>PLoS Pathogens</i> , <b>2014</b> , 10, e1003836	7.6	48
50	Oncolytic vesicular stomatitis virus expressing interferon- $\beta$ has enhanced therapeutic activity. <i>Molecular Therapy - Oncolytics</i> , <b>2016</b> , 3, 16001	6.4	46
49	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. <i>Nature Communications</i> , <b>2015</b> , 6, 6410	17.4	36
48	Model-based rational design of an oncolytic virus with improved therapeutic potential. <i>Nature Communications</i> , <b>2013</b> , 4, 1974	17.4	35
47	Over-expression of I $\kappa$ B-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. <i>Prostate</i> , <b>2009</b> , 69, 706-18	4.2	30
46	NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 7044-52	12.9	30
45	SnapShot: Cancer Immunotherapy with Oncolytic Viruses. <i>Cell</i> , <b>2019</b> , 176, 1240-1240.e1	56.2	29
44	Customized Viral Immunotherapy for HPV-Associated Cancer. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 847-859	18.9	29
43	Dimethyl fumarate potentiates oncolytic virotherapy through NF- $\kappa$ B inhibition. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	28
42	Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. <i>BJU International</i> , <b>2007</b> , 100, 303-9	5.6	28
41	Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. <i>Methods in Molecular Biology</i> , <b>2012</b> , 797, 127-40	1.4	27
40	NF- $\kappa$ B2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. <i>Cellular Signalling</i> , <b>2007</b> , 19, 1093-100	4.9	24
39	Development and applications of oncolytic Maraba virus vaccines. <i>Oncolytic Virotherapy</i> , <b>2018</b> , 7, 117-128		24
38	Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma. <i>International Journal of Cancer</i> , <b>2017</b> , 141, 1257-1264	12.6	23
37	Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3832-43	12.9	23
36	Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy. <i>ACS Infectious Diseases</i> , <b>2018</b> , 4, 1448-1467	8.5	23
35	Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 191	5.3	22

34	First-in-class small molecule potentiators of cancer virotherapy. <i>Scientific Reports</i> , <b>2016</b> , 6, 26786	4.9	21
33	Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. <i>BJU International</i> , <b>2008</b> , 101, 1302-9	5.6	19
32	Single-particle characterization of oncolytic vaccinia virus by flow virometry. <i>Vaccine</i> , <b>2016</b> , 34, 5082-5089	4.1	19
31	Regulation of I $\kappa$ B kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer. <i>Molecular Cancer Research</i> , <b>2007</b> , 5, 87-94	6.6	16
30	Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. <i>Journal of Virology</i> , <b>2013</b> , 87, 2363-6	6.6	15
29	Exploiting tumor epigenetics to improve oncolytic virotherapy. <i>Frontiers in Genetics</i> , <b>2013</b> , 4, 184	4.5	15
28	An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. <i>Prostate</i> , <b>2006</b> , 66, 1245-56	4.2	15
27	Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e102365	3.7	14
26	Ex vivo infection of live tissue with oncolytic viruses. <i>Journal of Visualized Experiments</i> , <b>2011</b> ,	1.6	13
25	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry. <i>Molecular Therapy</i> , <b>2021</b> , 29, 1984-2000	11.7	13
24	Enhancement of oncolytic virotherapy by vanadium(V) dipicolinates. <i>BioMetals</i> , <b>2019</b> , 32, 545-561	3.4	11
23	Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1007264	7.6	11
22	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. <i>Molecular Therapy - Oncolytics</i> , <b>2019</b> , 14, 179-187	6.4	11
21	Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	11
20	Immunotherapy for sarcomas: new frontiers and unveiled opportunities <b>2021</b> , 9,		11
19	Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization. <i>Membranes</i> , <b>2020</b> , 10,	3.8	10
18	SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. <i>Biosensors and Bioelectronics</i> , <b>2021</b> , 180, 113122	11.8	9
17	Development of a novel screening platform for the identification of small molecule inhibitors of human adenovirus. <i>Virology</i> , <b>2019</b> , 538, 24-34	3.6	8

16	High-throughput titration of luciferase-expressing recombinant viruses. <i>Journal of Visualized Experiments</i> , <b>2014</b> , 51890	1.6	6
15	The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy. <i>Communications Biology</i> , <b>2020</b> , 3, 254	6.7	5
14	Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. <i>BMJ Open</i> , <b>2020</b> , 10, e034714	3	5
13	A novel method of cell embedding for tissue microarrays. <i>Histopathology</i> , <b>2010</b> , 57, 323-9	7.3	5
12	Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. <i>Molecular Therapy - Oncolytics</i> , <b>2021</b> , 20, 306-324	6.4	5
11	Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection. <i>Molecular Therapy</i> , <b>2021</b> ,	11.7	2
10	Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern. <i>ACS Infectious Diseases</i> , <b>2021</b> , 7, 3034-3051	5.5	2
9	Viral Vectors for Treatment of Human Disease: Therapeutic and Manufacturing Challenges <b>2019</b> , 213-246		1
8	Influence of pH on the Cytotoxic Activity of Inositol Hexakisphosphate (IP6) in Prostate Cancer. <i>Frontiers in Oncology</i> , <b>2011</b> , 1, 40	5.3	1
7	Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy.. <i>Molecular Therapy - Oncolytics</i> , <b>2022</b> , 25, 146-159	6.4	1
6	Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta-analysis. <i>Hematological Oncology</i> , <b>2021</b> , 39, 448-464	1.3	0
5	Personalized oncology and BRAF melanoma: model development, drug discovery, and clinical correlation. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 1365-1378	4.9	0
4	Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.. <i>Nature Communications</i> , <b>2022</b> , 13, 1898	17.4	0
3	A Systematic Review of Evidence Supporting the Use of Autologous Cell Vaccines in the Treatment of Hematological Malignancies. <i>Blood</i> , <b>2020</b> , 136, 16-16	2.2	
2	Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 19, 240-252	6.4	
1	Actin-Related Protein 6 (Arp6) Influences Double-Strand Break Repair in Yeast. <i>Applied Microbiology</i> , <b>2021</b> , 1, 225-238		